Intravitreal pegcetacoplan may be linked with increased incidence of exudative AMD
- Posted on: Dec 27 2021
- Leave a response
A post hoc analysis of the Phase 2 prospective, randomized, sham injection–controlled FILLY trial of pegcetacoplan for the treatment of geographic atrophy (GA) focused on participants who developed new-onset, investigator-determined exudative age-related macular degeneration (eAMD) during the trial.
Source: AAO
Posted in: Uncategorized